相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Hsp90B enhances MAST1-mediated cisplatin resistance by protecting MAST1 from proteosomal degradation
Chaoyun Pan et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
PML/RARA inhibits expression of HSP90 and its target AKT
Maria Liliana Piredda et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Hsp90ab1 stabilizes LRP5 to promote epithelial-mesenchymal transition via activating of AKT and Wnt/β-catenin signaling pathways in gastric cancer progression
Huanan Wang et al.
ONCOGENE (2019)
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
T. P. Hughes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Heat shock proteins and cancer: intracellular chaperones or extracellular signalling ligands?
Stuart K. Calderwood
PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES (2018)
Targeting HSP90 dimerization via the C terminus is effective in imatinib-resistant CML and lacks the heat shock response
Sanil Bhatia et al.
BLOOD (2018)
Blockade of Y177 and Nuclear Translocation of Bcr-Abl Inhibits Proliferation and Promotes Apoptosis in Chronic Myeloid Leukemia Cells
Qianyin Li et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Hsp90 inhibitor induces KG-1a cell differentiation and apoptosis via Akt/NF-κB signaling
Jin-Hong Qin et al.
ONCOLOGY REPORTS (2017)
The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib
Fausto Castagnetti et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Stabilization of Notch1 by the Hsp90 Chaperone is Crucial for T-Cell Leukemogenesis
Zhaojing Wang et al.
CLINICAL CANCER RESEARCH (2017)
Heat Shock Protein 90 Regulates Subcellular Localization of Smads in Mv1Lu Cells
Jeeyong Lee et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2016)
Current Understanding of HSP90 as a Novel Therapeutic Target: An Emerging Approach for the Treatment of Cancer
Absarul Haque et al.
CURRENT PHARMACEUTICAL DESIGN (2016)
Development of Heat Shock Protein (Hsp90) Inhibitors To Combat Resistance to Tyrosine Kinase Inhibitors through Hsp90-Kinase Interactions
Meining Wang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia
J. L. Steegmann et al.
LEUKEMIA (2016)
A coiled-coil mimetic intercepts BCR-ABL1 dimerization
D. W. Woessner et al.
LEUKEMIA (2015)
The HSP90 inhibitor ganetespib: A potential effective agent for Acute Myeloid Leukemia in combination with cytarabine
M. Lazenby et al.
LEUKEMIA RESEARCH (2015)
Maximizing the Therapeutic Potential of HSP90 Inhibitors
Lisa M. Butler et al.
MOLECULAR CANCER RESEARCH (2015)
MEK-Dependent Negative Feedback Underlies BCR-ABL-Mediated Oncogene Addiction
Jennifer Asmussen et al.
CANCER DISCOVERY (2014)
Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase
Andreas Hochhaus et al.
BLOOD (2013)
Experimentally Guided Structural Modeling and Dynamics Analysis of Hsp90-p53 Interactions: Allosteric Regulation of the Hsp90 Chaperone by a Client Protein
Kristin Blacklock et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2013)
Induction of apoptosis by directing oncogenic Bcr-Abl into the nucleus
Zheng-Lan Huang et al.
ONCOTARGET (2013)
Pushing the limits of targeted therapy in chronic myeloid leukaemia
Thomas O'Hare et al.
NATURE REVIEWS CANCER (2012)
Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population
Fabio Efficace et al.
BLOOD (2011)
Assessment of downstream effectors of BCR/ABL protein tyrosine kinase using combined proteomic approaches
Chia Fang Lee et al.
PROTEOMICS (2010)
Targeting the dynamic HSP90 complex in cancer
Jane Trepel et al.
NATURE REVIEWS CANCER (2010)
Molecular biology of bcr-abl1-positive chronic myeloid leukemia
Alfonso Quintas-Cardama et al.
BLOOD (2009)
Controlling subcellular localization to alter function: Sending oncogenic Bcr-Abl to the nucleus causes apoptosis
Andrew S. Dixon et al.
JOURNAL OF CONTROLLED RELEASE (2009)
14-3-3 Ligand Prevents Nuclear Import of c-ABL Protein in Chronic Myeloid Leukemia
Manuela Mancini et al.
TRAFFIC (2009)
Signaling Networks Associated With BCR-ABL-Dependent Transformation
Lori A. Hazlehurst et al.
CANCER CONTROL (2009)
Crossing the nuclear envelope: Hierarchical regulation of nucleocytoplasmic transport
Laura J. Terry et al.
SCIENCE (2007)
Heat shock protein 90 - A potential therapeutic target in leukemic progenitor and stem cells harboring mutant BCR-ABL resistant to kinase inhibitors
Cong Peng et al.
CELL CYCLE (2007)
c-Abl-independent p73 stabilization during gemcitabine-or 4′-thio-β-D-arabinofuranosylcytosine-induced apoptosis in wild-type and p53-null colorectal cancer cells
JV Thottassery et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia
R Ren
NATURE REVIEWS CANCER (2005)
JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis
LS Steelman et al.
LEUKEMIA (2004)
Regulation of the C-Abl and Bcr-Abl tyrosine kinases
O Hantschel et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2004)
The Hsp90 chaperone complex as a novel target for cancer therapy
MP Goetz et al.
ANNALS OF ONCOLOGY (2003)
Imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia
SG O'Brien et al.
SEMINARS IN HEMATOLOGY (2003)
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
ME Gorre et al.
SCIENCE (2001)
Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase
P Vigneri et al.
NATURE MEDICINE (2001)
分享论文
